Novel crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid 471

Abstract

New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

1 - 38 . (canceled) 
     
     
         39 . A crystalline form of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid having an X-ray diffraction pattern with peaks at the following 2-theta values measured using CuKa radiation: 18.7 and 11.7°. 
     
     
         40 . A crystalline compound as claimed in  claim 39  having an X-ray powder diffraction pattern with peaks at the following 2-theta values measured using CuKa radiation: 18.7, 11.7 and 19.2°. 
     
     
         41 . A crystalline form of a compound as claimed in  claim 39  having an X-ray powder diffraction pattern with peaks at the following 2-theta values measured using CuKa radiation: 18.7, 11.7, 19.2, 7.8, 14.1, 14.9 and 9.4°. 
     
     
         42 . A crystalline form of a compound as claimed in  claim 39  having an X-ray powder diffraction pattern with peaks at the following 2-theta values measured using CuKa radiation: 18.7, 11.7, 19.2, 7.8, 14.1, 14.9, 9.4, 15.6, 16.1 and 9.6°. 
     
     
         43 . A crystalline compound as claimed in  claim 39  having an X-ray diffraction pattern, using CuKa radiation, substantially the same as shown in  FIG. 3 . 
     
     
         44 . A pharmaceutical composition, which comprises a compound according to  claim 39  in association with a pharmaceutically-acceptable diluent or carrier. 
     
     
         45 . A method of producing a 11βHSD1 inhibitory effect by administering an effective amount of a compound according to  claim 39  to a mammal in need of such treatment. 
     
     
         46 . A method according to  claim 45  wherein the 11βHSD1 inhibitory effect is to treat type 2 diabetes.